Oruka Therapeutics, Inc.
ORKA
$29.57
$1.746.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 36.16% | 53.97% | -- | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 15.81% | 32.27% | 265.53% | ||
| Operating Income | -15.81% | -32.27% | -265.53% | ||
| Income Before Tax | -5.78% | -10.48% | -- | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -5.78% | -10.48% | -- | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -5.78% | -10.48% | -196.72% | ||
| EBIT | -15.81% | -32.27% | -265.53% | ||
| EBITDA | -15.76% | -- | -- | ||
| EPS Basic | 62.66% | 93.40% | 97.39% | ||
| Normalized Basic EPS | 63.96% | 91.61% | -- | ||
| EPS Diluted | 62.66% | 93.40% | 97.39% | ||
| Normalized Diluted EPS | 63.96% | 91.61% | -- | ||
| Average Basic Shares Outstanding | 193.51% | 1,216.32% | -- | ||
| Average Diluted Shares Outstanding | 193.51% | 1,216.32% | 8,836.45% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||